Natural product-derived therapy for cardiac hypertrophy and fibrosis: A pharmaceutical mixture encompassing βCryptoxanthin, Mangiferin & Glycyrrhetinic acid (CMG) decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via up regulation of its target gene, 16/June/2017, 7.07 pm
https://genomediscovery.org/wp-content/uploads/2018/06/Cryptoxanthin-Mangiferin-Glycyrrhetinic-acid-attenuate-pathogenesis-associated-with-cardiac-hypertrophy-and-fibrosis.jpg
960
720
Dr Boomi's Genom-2-Discovery Center
https://genomediscovery.org/wp-content/uploads/2018/06/Cryptoxanthin-Mangiferin-Glycyrrhetinic-acid-attenuate-pathogenesis-associated-with-cardiac-hypertrophy-and-fibrosis.jpg
Introduction: What they say: A recent study from the Institute of Pharmacology and Toxicology, Technical University Munich (TUM), 80802, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich…
read more